Eli Lilly: the trials and tribulations of antibody patents
Working in the biomedicine department at Eli Lilly, Duane Marks says his work entails “pretty much all aspects touching on IP relating to our biomedicines”. Through the course of his career Marks, who is patent counsel in bioproducts, has practised in numerous areas including diagnostics, research tools, and medical devices.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.
5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.